The Board of Huntsworth plc has announced that, due to his other external commitments, Andy Boland has decided to step down as Chair of the Huntsworth Audit Committee (the committee), and Pat Billingham, another independent non-executive director and an existing member of the Committee, will be appointed in his place. This change will take effect on 22 March 2017. Following the change, Andy Boland will continue to remain a member of the Committee.
Huntsworth Limited is a United Kingdom-based intermediate holding company. The Company is engaged in healthcare and communication activities. The Company, through its subsidiaries, is focused on health that provides marketing and medical communications services to healthcare clients, which are primarily large and mid-size pharmaceuticals and biotechnology companies. It also provides a range of communications and advisory services, including strategic communications, public affairs, investor relations and consumer marketing. The Companyâs financial instruments comprise bank loans, bank overdrafts, loan notes, and cash and short-term deposits. The Companyâs geographical areas include the United Kingdom, Europe, the United States and the rest of the world. The Companyâs subsidiaries operate in approximately 28 in the United Kingdom and Europe.